186 related articles for article (PubMed ID: 16112008)
1. Galectin-3 expression in parathyroid carcinoma: immunohistochemical study of 26 cases.
Bergero N; De Pompa R; Sacerdote C; Gasparri G; Volante M; Bussolati G; Papotti M
Hum Pathol; 2005 Aug; 36(8):908-14. PubMed ID: 16112008
[TBL] [Abstract][Full Text] [Related]
2. Defining a molecular phenotype for benign and malignant parathyroid tumors.
Fernandez-Ranvier GG; Khanafshar E; Tacha D; Wong M; Kebebew E; Duh QY; Clark OH
Cancer; 2009 Jan; 115(2):334-44. PubMed ID: 19107770
[TBL] [Abstract][Full Text] [Related]
3. Galectin-3 and Ki-67 expression in multiglandular parathyroid lesions.
Saggiorato E; Bergero N; Volante M; Bacillo E; Rosas R; Gasparri G; Orlandi F; Papotti M
Am J Clin Pathol; 2006 Jul; 126(1):59-66. PubMed ID: 16753595
[TBL] [Abstract][Full Text] [Related]
4. Expression of Ki-67, galectin-3, fragile histidine triad, and parafibromin in malignant and benign parathyroid tumors.
Wang O; Wang CY; Shi J; Nie M; Xia WB; Li M; Jiang Y; Guan H; Meng XW; Xing XP
Chin Med J (Engl); 2012 Aug; 125(16):2895-901. PubMed ID: 22932087
[TBL] [Abstract][Full Text] [Related]
5. Galectin-3 expression in follicular tumours: an immunohistochemical study of its use as a marker of follicular carcinoma.
Ito Y; Yoshida H; Tomoda C; Miya A; Kobayashi K; Matsuzuka F; Yasuoka H; Kakudo K; Inohara H; Kuma K; Miyauchi A
Pathology; 2005 Aug; 37(4):296-8. PubMed ID: 16194828
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of galectin-3 immunohistochemistry in differential diagnosis between thyroid follicular carcinoma and follicular adenoma.
Jakubiak-Wielganowicz M; Kubiak R; Sygut J; Pomorski L; Kordek R
Pol J Pathol; 2003; 54(2):111-5. PubMed ID: 14575419
[TBL] [Abstract][Full Text] [Related]
7. Parathyroid neoplasms: clinical, histopathological, and tissue microarray-based molecular analysis.
Stojadinovic A; Hoos A; Nissan A; Dudas ME; Cordon-Cardo C; Shaha AR; Brennan MF; Singh B; Ghossein RA
Hum Pathol; 2003 Jan; 34(1):54-64. PubMed ID: 12605367
[TBL] [Abstract][Full Text] [Related]
8. Thyroid peroxidase and galectin-3 immunostaining in differentiated thyroid carcinoma with clinicopathologic correlation.
Savin S; Cvejic D; Isic T; Paunovic I; Tatic S; Havelka M
Hum Pathol; 2008 Nov; 39(11):1656-63. PubMed ID: 18657294
[TBL] [Abstract][Full Text] [Related]
9. Utility of galectin 3 expression in thyroid aspirates as a diagnostic marker in differentiating benign from malignant thyroid neoplasms.
Aron M; Kapila K; Verma K
Indian J Pathol Microbiol; 2006 Jul; 49(3):376-80. PubMed ID: 17001889
[TBL] [Abstract][Full Text] [Related]
10. Expression of Galectin-3 and Galectin-7 in thyroid malignancy as potential diagnostic indicators.
Than TH; Swethadri GK; Wong J; Ahmad T; Jamil D; Maganlal RK; Hamdi MM; Abdullah MS
Singapore Med J; 2008 Apr; 49(4):333-8. PubMed ID: 18418527
[TBL] [Abstract][Full Text] [Related]
11. Expression of nm23 antimetastatic gene product in parathyroid hyperplasia, adenoma and carcinoma. An immunohistological assessment.
Al-Maghrabi JA; Asa SL
Saudi Med J; 2005 May; 26(5):728-31. PubMed ID: 15951858
[TBL] [Abstract][Full Text] [Related]
12. Immunostaining of galectin-3 and CD44v6 using fine-needle aspiration for distinguishing follicular carcinoma from adenoma.
Maruta J; Hashimoto H; Yamashita H; Yamashita H; Noguchi S
Diagn Cytopathol; 2004 Dec; 31(6):392-6. PubMed ID: 15540177
[TBL] [Abstract][Full Text] [Related]
13. Parafibromin, APC, and MIB-1 Are Useful Markers for Distinguishing Parathyroid Carcinomas From Adenomas.
Hosny Mohammed K; Siddiqui MT; Willis BC; Zaharieva Tsvetkova D; Mohamed A; Patel S; Sharma J; Weber C; Cohen C
Appl Immunohistochem Mol Morphol; 2017; 25(10):731-735. PubMed ID: 27490759
[TBL] [Abstract][Full Text] [Related]
14. Expression of cell cycle inhibitor p27 and Ki-67 in human adrenocortical neoplasms.
Nakazumi H; Sasano H; Iino K; Ohashi Y; Orikasa S
Mod Pathol; 1998 Dec; 11(12):1165-70. PubMed ID: 9872646
[TBL] [Abstract][Full Text] [Related]
15. Galectin-3 is highly expressed in nonencapsulated papillary thyroid carcinoma but weakly expressed in encapsulated type; comparison with Hector Battifora mesothelial cell 1 immunoreactivity.
Torregrossa L; Faviana P; Camacci T; Materazzi G; Berti P; Minuto M; Elisei R; Vitti P; Miccoli P; Basolo F
Hum Pathol; 2007 Oct; 38(10):1482-8. PubMed ID: 17597183
[TBL] [Abstract][Full Text] [Related]
16. Galectin-3: a useful biomarker for differential diagnosis of brain tumors.
Park SH; Min HS; Kim B; Myung J; Paek SH
Neuropathology; 2008 Oct; 28(5):497-506. PubMed ID: 18384511
[TBL] [Abstract][Full Text] [Related]
17. Parathyroid hyperplasia, adenomas, and carcinomas: differential expression of p27Kip1 protein.
Erickson LA; Jin L; Wollan P; Thompson GB; van Heerden JA; Lloyd RV
Am J Surg Pathol; 1999 Mar; 23(3):288-95. PubMed ID: 10078919
[TBL] [Abstract][Full Text] [Related]
18. PCNA-LII, Ki-67 immunostaining, p53 activity and histopathological variables in predicting the clinical outcome in patients with parathyroid carcinoma.
Lumachi F; Ermani M; Marino F; Iacobone M; Baldessin M; Cappuzzo G; Zanella S; Favia G
Anticancer Res; 2006; 26(2A):1305-8. PubMed ID: 16619538
[TBL] [Abstract][Full Text] [Related]
19. Cell proliferation marker MCM2, but not Ki67, is helpful for distinguishing between minimally invasive follicular carcinoma and follicular adenoma of the thyroid.
Cho Mar K; Eimoto T; Nagaya S; Tateyama H
Histopathology; 2006 Jun; 48(7):801-7. PubMed ID: 16722928
[TBL] [Abstract][Full Text] [Related]
20. Parafibromin immunoreactivity: its use as an additional diagnostic marker for parathyroid tumor classification.
Juhlin CC; Villablanca A; Sandelin K; Haglund F; Nordenström J; Forsberg L; Bränström R; Obara T; Arnold A; Larsson C; Höög A
Endocr Relat Cancer; 2007 Jun; 14(2):501-12. PubMed ID: 17639063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
